Ann: SUDA Appoints Dr Michael Baker CEO, page-2

My hunch was right -

"Perth, Australia – 27 November 2019: SUDA Pharmaceuticals Limited (ASX: SUD), a leader in oro-mucosal drug delivery, advises that Dr Michael Baker has been appointed CEO, commencing 2 January 2020.
Michael Baker joins SUDA Pharmaceuticals from the leading Australian life science fund, Bioscience Managers, where he was based from 2017. As an Investment Manager, he was responsible for deal sourcing from networks, conferences, universities and research institutes. He also conducted the due diligence to shortlist investment opportunities and managed portfolios, specifically helping investee companies with corporate and operational strategies and fund raisings.
Before that, Michael Baker was a project manager at Hexima Limited which specialises in developing agricultural and pharmaceutical products. He was a senior manager and his role was to lead and motivate a team of 4-8 research scientists and drive project development, ensuring timely completion of milestones, including helping guide a drug candidate from discovery to clinical trials.
Michael Baker is replacing Paul Hopper, who will step down after a hand-over period, as Executive Chairman to resume as Non-Executive Chairman for SUDA Pharmaceuticals.
Paul Hopper said that he welcomed Michael’s new role as CEO. “I am delighted that an executive of Michael’s calibre has agreed to accept the role of CEO. Michael’s expertise across commercialisation of technologies, scientific research and financial investments is a core asset, which is important for SUDA as it repositions itself. Business development will be a major focus of the new role and Michael’s high energy personality will help SUDA focus on the year ahead.”
“With refreshed company management going forward we are striving to rebuild company value and shareholder confidence.” said Mr Hopper."
.